Abemaciclib mesylate (LY2835219)

For research use only. Not for use in humans.

目录号:S7158 中文名称:甲磺酸阿贝西尼

Abemaciclib mesylate (LY2835219) Chemical Structure

CAS No. 1231930-82-7

Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 4644.52 现货
RMB 2203.44 现货
RMB 3333.88 现货
RMB 6544.35 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Abemaciclib mesylate (LY2835219)发表文献58篇:

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。
靶点
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
2 nM 10 nM
体外研究

LY2835219是一种口服有效的细胞周期蛋白依赖性激酶(CDK)抑制剂,靶向作用于CDK4(cyclin D1)和CDK6(cyclin D3)细胞周期通路,具有潜在的抗肿瘤活性。LY2835219特异性抑制CDK4和6,从而在早G1期抑制视网膜母细胞瘤(Rb)蛋白磷酸化。抑制Rb磷酸化,防止CDK-介导的G1-S期转换,从而使细胞周期停滞在G1期,抑制DNA合成,且抑制癌细胞生长。某些类型的癌症中丝/苏氨酸激酶CDK4/6的过表达,导致细胞周期调节失控。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human COLO205 cells MmPDSpVv[3Srb36gZZN{[Xl? M1LEdFI1KGh? NXu1TnA2UW6qaXLpeIlwdiCxZjDDSGs1NzZiaX6gbJVu[W5iQ1;MU|IxPSClZXzsd{Bie3Onc4Pl[EBieyCvYYjpcZVuKGOnbHygZ5lkdGViYYLy[ZN1KGG2IFexJJBp[XOnIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcx?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
human COLO205 cells M4PWWmZ2dmO2aX;uJIF{e2G7 M{j4d|I1KGh? NIfmU|FKdmirYnn0bY9vKG:oIFPET|QwPiCrbjDoeY1idiCFT1zPNlA2KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJIFnfGW{IEK0JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKGyjc3XyMZNk[W6waX7nJIZtfW:{ZYPj[Y5k\SCvaXPyc5Bt[XSnIHP5eI9u\XS{aXOgZY5idHm|aYO= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
insect cells  NUH5[G1oTnWwY4Tpc44h[XO|YYm= NYftUnQ{PTBibXnudy=> MXHJcohq[mm2aX;uJI9nKGi3bXHuJGNFUzRxY4njcIlvKERzIHX4dJJme3OnZDDpckBqdnOnY4SgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNVWkZiYX\0[ZIhPTBibXnud{BjgSCvaXPyc5Bt[XSnIIPjbY51cWyuYYTpc44h[2:3boTldkwhUUN3ME2yJI5O NF\uXIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
insect cells  NIHuNI9HfW6ldHnvckBie3OjeR?= NVLqe5dZPTBibXnudy=> MYTDc41x\XSrdHn2[UBqdmirYnn0bY9vKG:oIHj1cYFvKEOGS{SvZ5lkdGmwIFSxJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2aX;uJI9nKEOWUl[gZYZ1\XJiNUCgcYlveyCkeTDNbYNp[WWuaYOtUYVvfGWwIIDsc5Qh[W6jbInzbZMhcW5icILld4Vv[2Vib3[gRXRRNCCNaU2wMlYhdk1? MmXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUW1O|EoRjJ4MUG1OVcyRC:jPh?=
HCT116 MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NUXHUHp3PzJiaILz M1rxXGlEPTBiPTCwMlU1KM7:TR?= M2jw[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMU[1N|QyLz5|MEG2OVM1OTxxYU6=
MCF7 NUPqfHRLSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M{jPVVczKGi{cx?= MonSTWM2OCB;IECuO|Eh|ryP MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4NUO0NUc,OzBzNkWzOFE9N2F-
PANC1 NGfZeGtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NUSzOI0yPzJiaILz NW\DfFJtUUN3MDC9JFUvQTRizszN NFryNpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1OSd-M{CxOlU{PDF:L3G+
Sf9 MWrGeY5kfGmxbjDhd5NigQ>? NVvJSHo2UW6qaXLpeIlwdiCxZjDDSGsyN0O7Y3zpckBDKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcnHsJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgeZNqdmdiaHnzeI9v\SCKMTDhd{B{fWK|dILheIUhcW5icILld4Vv[2Vib3[gX4didW2jLUOzVH1CXFBuIFnDOVAhRSByLkO3NUDPxE1w MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd2MUi1N{c,OjZ5NEG4OVM9N2F-
Sf9 MnflSpVv[3Srb36gZZN{[Xl? MVW5NEBucW6| MnfsTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqNDD0c{A{ODNicnXzbYR2\XNrL3P5Z4xqdiCGMTCoOEB1dyB{OUWgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiC|ZkmgZ4VtdHNidYPpcochSy22ZYLtbY5idCC{ZYTpco9jdGG|dH;tZUBnemGpbXXueEBieyC|dXLzeJJifGViYX\0[ZIhQTBibXnud{BjgSCdZ3HtcYEuOzOSXVHUVEBj[XOnZDDtbYNzd2KndHGgd4NqdnSrbHzheIlwdiClb4XueIlvNCCNaTC9JFAvODB{IN88UU4> Mn3zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN|YoRjJ5MUexNFM3RC:jPh?=
Sf9 MYrGeY5kfGmxbjDhd5NigQ>? NE\pcJc6OCCvaX7z MkPHTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNNjCoNUB1dyB|Mk[gdoV{cWS3ZYOpM4N6[2yrbjDENUApPCC2bzCyPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgeZNqdmdiQz30[ZJucW6jbDDy[ZRqdm:kbHHzeI9u[SCocnHncYVvfCCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDb[4FudWFvM{PQYWFVWCCkYYPl[EBucWO{b3LleIEhe2OrboTpcIxiNCCNaTC9JFAvODFizszNMi=> NEfsOI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G3NVA{Pid-MkexO|ExOzZ:L3G+
Sf21 MlvXSpVv[3Srb36gZZN{[Xl? M3vDUGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXN4LYTh[4dm\CCFRFu3M4N6[2yrbjDIM24ufGW{bXnuZYwhT1OWLYTh[4dm\CCPQWSxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yClZHu3JJN2[nO2cnH0[UBx\XC2aXTlMEBMcSB;IEOuPVEh|ryPLh?= MmLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN|YoRjJ5MUexNFM3RC:jPh?=
COLO205 NHzMWVJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NV[5[5B3QTZiaILz M3zoVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU|IxPSClZXzsd{Bi\nSncjC5OkBpenNiYomgR2NMNThiYYPzZZktKEmFNUCgQUAxNjR4IN88UU4> NVjEe4pORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwO|QzPTRpPkK5NFc1OjV2PD;hQi=>
U87MG M{nvcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NH25O284OiCqcoO= M3\u[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFTBVGkhe3SjaX7pcoch[mG|ZXSgZZN{[XluIFnDOVAhRSByLkC0PFEh|ryPLh?= NUW1WFBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyOFc5PTdpPkK5NlQ4QDV5PD;hQi=>
Sf9 MlHxSpVv[3Srb36gZZN{[Xl? M4rueWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzRiKGO0JJRwKEV|MEOgdoV{cWS3ZYOpM2N6[2yrbjDENUApWTRidH:gTVI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDSZkBxem:2ZXnuJEg4PzNidH:gPVI5KHKnc3nkeYV{MSCjczDzeYJ{fHKjdHWgbY4heHKnc3XuZ4Uhd2ZiW{OzVH0uSVSSIHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmdibXX0bI9lNCCLQ{WwJF0hOC5yMEKg{txONg>? MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 M2DkWmZ2dmO2aX;uJIF{e2G7 MYG5NEBucW6| NFLCNndKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGNFUzZiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegbIl{fG:wZTDINUB{fWK|dILheIUh[W[2ZYKgPVAhdWmwczDifUBCTFBvR3zvJIF{e2G7LDDJR|UxKD1iMD6wNFc5KM7:TT6= NUXm[YMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Nlk5OzJpPkK5OFI6QDN{PD;hQi=>
Sf9 MnrxSpVv[3Srb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs1KCiPMTD0c{BCOzJ4IILld4llfWW|KT;DfYNtcW5iREGgLHE1KHSxIFmyPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgeZNqdmdiUnKgdJJwfGWrbjCoO|c{KHSxIEmyPEBz\XOrZIXld{kh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFt|M2DdMWFVWCCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODFizszNMi=> Mo\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 M4DkUWZ2dmO2aX;uJIF{e2G7 MXq5NEBucW6| MULJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFPET|EwS3mlbHnuJGQ{KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIHjpd5RwdmViSEGgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgRWRRNUeubzDhd5NigSxiSVO1NEA:KDBwMEW2JO69VS5? NWS1coJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Nlk5OzJpPkK5OFI6QDN{PD;hQi=>
MDA-MB-231 MoXORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idg>? NVzkUnkyPzJiaILz MoezRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGG|c3H5MEBKSzVyIE2gNE4yQTFizszNMi=> MnrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
COLO205 MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFv MlKwPVYhcHK| MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEORTF:yNFUh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IFPDT|gh[XO|YYmsJGlEPTBiPTCwMlIyPyEQvF2u MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3OUK3OEc,Ojl2NUmyO|Q9N2F-
MDA-MB-468 MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFv MnrnPVYhcHK| M4T5UmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTR4ODDj[YxteyCjZoTldkA6PiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDRwOEC4JO69VS5? NXLO[4NYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVkzPzRpPkK5OFU6Ojd2PD;hQi=>
COLO205 MXPJcohq[mm2aX;uJI9nKEOGS{SgbY4hcHWvYX6= NXv4UGttOC5zIITvJFExKHWP M4iwN|I1KGi{cx?= NXXuc4tyUW6qaXLpeIlwdiCxZjDDSGs1KGmwIHj1cYFvKEORTF:yNFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIITveIFtKFKkIIDyc5RmcW5ibHX2[Ywh[XRiMD6xJJRwKDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q> MnrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=
COLO205 MVrD[YxtKGO7Y3zlJIF{e2G7 MX;1dEB1dyBzMDD1US=> NEDSbpozPCCqcoO= NVrZT29MS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|IwVSCyaHHz[UB2eCC2bzCxNEB2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDGRWNUKGGwYXz5d4l{ NXLa[Hh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVkzPzRpPkK5OFU6Ojd2PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Rb(S780) / Rb / p21; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated concentrations (A)

p-ERK / ERK / p-Akt / Akt / p-mTOR(S2448) / mTOR; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated time points (B).

pRb(S795) / E2F1 / Cyclin A2 / Cyclin E2; 

PubMed: 27748766     


(c) MCF-7 and MR cells were treated with 100 nm LY2835219 and collected at indicated times. Immunoblots were performed with the indicated antibodies. (d) MCF-7 and MR cells were treated with increasing concentrations of LY2835219 and harvested after 24 h; lysates were then subjected to immunoblotting.

26909611 27748766
Growth inhibition assay
Cell viability; 

PubMed: 26909611     


Cell viability of OSC-19, FaDu, and YD-10B cells treated with LY2835219 at indicated concentrations. Data are representative of three independent experiments: mean ± SEM.

26909611
体内研究 LY2835219-MsOH处理脑的剂量百分比为0.5–3.9%。LY2835219-MsOH处理皮下和颅内胶质瘤模型(U87MG),抑制肿瘤生长,这种作用存在剂量依赖性,不管是单独处理,还是与Temozolomide联用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 Water 100 mg/mL (165.92 mM)
DMSO 83 mg/mL (137.71 mM)
Ethanol '''24 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
100mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 602.7
化学式

C27H32F2N8.CH4O3S

CAS号 1231930-82-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05169567 Not yet recruiting Drug: Abemaciclib|Drug: Fulvestrant|Drug: Placebo Breast Neoplasm|Neoplasm Metastasis Eli Lilly and Company January 14 2022 Phase 3
NCT04791384 Not yet recruiting Drug: Abemaciclib|Drug: Elacestrant Breast Cancer Criterium Inc. January 1 2022 Phase 1|Phase 2
NCT04967521 Recruiting Drug: Abemaciclib|Drug: Placebo Advanced Dedifferentiated Liposarcoma Sarcoma Alliance for Research through Collaboration|Eli Lilly and Company November 11 2021 Phase 3
NCT04750928 Recruiting Drug: Abemaciclib Neurofibromatosis 1 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) November 29 2021 Phase 1|Phase 2
NCT04941274 Recruiting Drug: Abemaciclib Kaposi Sarcoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 29 2021 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is your product S7158 LY2835219 “mesylate salt form”?

  • 回答:

    Our S7158 LY2835219 is mesylate salt form.

免费分装抑制剂

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)供应商 | 采购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)价格 | Abemaciclib mesylate (LY2835219)生产 | 订购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID